Genmab A/S GMAB 深 沪
等待开盘 08-25 09:30:00 美东时间
33.02
-0.430
-1.29%
华盛通- 最 高33.32
- 今 开32.82
- 成交量 324.65万股
- 最 低 32.74
- 昨 收 33.45
- 总市值 2029.48万
- 52周最高 35.43
- 市盈率 静 21.43
- 换手率 0.53%
- 52周最低 23.62
- 委 比 -98.02%
- 总股本 0.01亿
- 历史最高 49.07
- 量 比 0.89
- 振 幅 1.73%
- 历史最低 16.24
- 每 手 1
- 风险率 2.64%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioNTech Highlights Late-Stage Lung Cancer Pipeline Momentum and First Global Data for Pumitamig/Elfetabart Drozuntecan Novel-Novel Combination at WCLC 2026
BioNTech will present new clinical data at the 2026 World Conference on Lung Cancer, highlighting advancements in its lung cancer treatment pipeline. Key updates include first combination data for pumitamig (a PD-(L)1xVEGF bispecific immunomodulator) with elfetabart drozuntecan (a B7H3-targeted ADC) in lung cancer, and updated overall survival data for gotistobart in second-line squamous NSCLC. The company is advancing over 16 clinical trials, in...
08-20 09:30
美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
08-10 19:24
Guggenheim Maintains Buy on Genmab, Raises Price Target to $42
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.
08-08 00:59
盘前：纳指期货涨0.59% 市场静待7月非农
周五全球股市小幅上涨，有望录得自5月以来最强劲的单周涨幅，交易员在关键的美国月度非农就业报告公布前保持谨慎，避免进行大规模押注。与此同时，由于霍尔木兹海峡重...
08-07 20:20
Genmab’s Earnings Call Highlights Growth, Upgraded Outlook
Genmab (Otc) (($GMAB)) has held its Q2 earnings call. Read on for the main high...
08-07 08:26
Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est
Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billion-$4.525 billion vs $4.355 billion estimate.
08-07 03:52
BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer
<p>German biotech company BioNTech announced the appointment of Guido Oelkers, Ph.D., as its new CEO, succeeding Prof. Ugur Sahin. Oelkers, a seasoned executive with over 30 years of experience in biotechnology and pharmaceuticals, will join BioNTech from Sobi, where he has served as CEO since 2017, successfully quadrupling the company's revenues. He will focus on advancing BioNTech's late-stage oncology pipeline and transitioning the company int...
08-03 09:00
AbbVie, Genmab announce late-stage trial setback for lymphoma therapy
AbbVie (ABBV) and Genmab (GMAB) announced that their jointly developed bispecific antibody epcoritamab, marketed as Epkinly in the U.S., failed to meet the primary endpoint in a late-stage trial for p...
07-24 19:54
美股大行评级 | 富国银行上调闪迪目标价从1250美元升至1620美元；最高132美元！高盛、大小摩等多家机构上调通用汽车目标价
今日重点评级关注：HC Wainwright & Co.：维持IREN"买入"评级，目标价从85美元升至90美元；BTIG：维持FTAI Aviation"买入"评级，目标价从340美元升至400美元
07-23 13:42
